Apeloa Pharmaceutical Co.,Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Puluo Pharmaceutical Co., Ltd. is a well-known private enterprise, Hengdian Group's pharmaceutical industry development platform, and a listed company on the main board of the Shenzhen Stock Exchange. The company ranks among the top 40 pharmaceutical industry enterprises in China, 25th in the "Top 100 Industrial Enterprises with Strength" (2nd in Zhejiang), 2nd in the "Raw Material Drug Export" (1st in Zhejiang), 5th in the CDMO enterprise list of Yaozhiwang, and 14th in the "Top 100 Most Valuable Companies Listed on the Chinese Main Board". It has also been selected as one of the second batch of Zhejiang Province's "Eagle Action" cultivation enterprises. In recent years, it has been awarded honors such as the "Industrial Strong City Contribution Award" in Dongyang City and the "Top Ten Taxpayers" in Jinhua and Dongyang City. After more than 30 years of development, the company has developed excellent pharmaceutical research and manufacturing capabilities. It has established API Technology Centers, CDMO R&D Centers, and Pharmaceutical Research Institutes at its headquarters in Hengdian, as well as in Shanghai, Boston, and Hangzhou in the United States; We have established production bases in Dongyang headquarters in Zhejiang, Weifang in Shandong, Dongzhi in Anhui, and Quzhou in Zhejiang, forming three main businesses: raw materials, CDMO, and preparations. The company's API business has accumulated a large amount of technical achievements and talent resources, leading and continuing to invest heavily in environmental governance, technological transformation, product research and development, and other aspects in the Chinese API industry. We have formed a strong competitive advantage in terms of cost, quality, EHS, and technology, and have become a leading enterprise in domestic specialty raw materials. As the core service provider of CDMO business in the global innovative pharmaceutical industry chain, Puluo Pharmaceutical has formed long-term strategic partnerships with top domestic and foreign bigpharma and biotech companies, with a solid foundation and a steady growth trend. The pharmaceutical business adheres to differentiation and globalization strategies to achieve rapid development. Eight varieties have passed the approval or consistency evaluation of the new four categories, creating well-known domestic brands such as "Baishixin" and "Tianliwei". Established the integration of raw material pharmaceutical preparations and the advantage of high-tech barriers, the company's first high-end sustained-release generic drug has been listed in the United States. The company is in line with international standards and has established a high standard quality management system and EHS management system, safeguarding the healthy development of the enterprise. The company actively fulfills its social responsibility and leads the industry in the management of "three wastes"; Actively participating in social welfare activities such as paired poverty alleviation, accident rescue, and anti epidemic donations, has received widespread praise from society. The company adheres to driving high-quality development through technological innovation, continues to increase research and development investment, establishes a research and development innovation system around three major businesses, and jointly builds innovation platforms with universities. It has established certain advantages in sub fields such as chiral synthesis, characteristic continuous reaction, biocatalysis, and micro pellet controlled release; At the same time, the company embraces intelligent manufacturing and vigorously promotes the construction of "continuity, automation, digitization, and intelligence" in the manufacturing end. The company adheres to the core values of "co creation and co prosperity" and the core culture of "benevolence, moderation, teamwork, and execution", practices the mission of "technology creation, service health", implements the development strategy of "making high-quality raw materials, strengthening CDMO, and making excellent preparations", and actively spreads the corporate culture of "happy learning, happy sports, and happy work". Facing the future, the people of Puluo are down-to-earth and full of pride, making great strides towards achieving high-quality development of the enterprise and the grand vision of becoming a leading enterprise in China's technology-based pharmaceutical manufacturing. |
| Headquarter | Jinhua |
| Establish Date | 5/6/1997 |
| Listed Code | 000739.SZ |
| Listed Date | 5/9/1997 |
| Chairman | Wishing Fang Meng. |
| CEO | Xu Xinliang. |
| Website | www.apeloa.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
